Back

Jasper Therapeutics appoints regulatory and clinical development executives after Kira merger

Verifying
  • Jasper appointed Lisa Pitt and Shiguang Liu to senior regulatory and clinical-development roles.
  • Three employees received options for 243,000 shares at a $0.6328 exercise price.
  • The appointments followed Jasper’s merger with Kira Pharmaceuticals, announced September 15, 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Jasper Therapeutics appoints regulatory and clinical development executives after Kira merger - CoinPost Terminal